Phase Ib study of sabatolimab ( MBG453 ), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes
American Journal of Hematology · 2024-02 · 99 (2)
DOI: 10.1002/ajh.27161 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift American Journal of Hematology, online erschienen am 22.11.2023. Verfasst von Andrew M Brunner und 26 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Antibodies, Monoclonal. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Massachusetts General Hospital, Boston, Massachusetts, USA.
- Hospital Clínic, Barcelona, Spain.
- Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
- School of Medicine, Cardiff University, Cardiff, UK.
- Oregon Health & Science University, Portland, Oregon, USA.
- University Hospital Jena, Jena, Germany.
ORCID-Profile: Andrew M Brunner, Guillermo Garcia-Manero, Norbert Vey, Andrew H Wei
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Brunner, A. M., Esteve, J., Porkka, K., Knapper, S., Traer, E., Scholl, S., Garcia-Manero, G., Vey, N., Wermke, M., Janssen, J. J. W. M., Narayan, R., Fleming, S., Loo, S., Tovar, N., Kontro, M., Ottmann, O. G., Naidu, P., Sun, H., Han, M., …, & Wei, A. H. (2024). Phase Ib study of sabatolimab ( MBG453 ), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes. American Journal of Hematology, 99(2). https://doi.org/10.1002/ajh.27161
Vancouver
Brunner AM, Esteve J, Porkka K, Knapper S, Traer E, Scholl S, et al. Phase Ib study of sabatolimab ( MBG453 ), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes. American Journal of Hematology. 2024;99(2). doi:10.1002/ajh.27161
BibTeX
@article{Brunner2024,
author = {Brunner, Andrew M and Esteve, Jordi and Porkka, Kimmo and Knapper, Steve and Traer, Elie and Scholl, Sebastian and Garcia-Manero, Guillermo and Vey, Norbert and Wermke, Martin and Janssen, Jeroen J W M and Narayan, Rupa and Fleming, Shaun and Loo, Sun and Tovar, Natalia and Kontro, Mika and Ottmann, Oliver G and Naidu, Purushotham and Sun, Haiying and Han, May and White, Roisin and Zhang, Na and Mohammed, Anisa and Sabatos-Peyton, Catherine A and Steensma, David P and Rinne, Mikael L and Borate, Uma M and Wei, Andrew H},
title = {Phase Ib study of sabatolimab ( MBG453 ), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes},
journal = {American Journal of Hematology},
year = {2024},
volume = {99},
number = {2},
doi = {10.1002/ajh.27161}
}
EUVIMED